Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/21396
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGrossmann, Mathis-
dc.contributor.authorRamchand, Sabashini K-
dc.contributor.authorMilat, Frances-
dc.contributor.authorVincent, Amanda-
dc.contributor.authorLim, Elgene-
dc.contributor.authorKotowicz, Mark A-
dc.contributor.authorHicks, Jill-
dc.contributor.authorTeede, Helena J-
dc.date2019-07-18-
dc.date.accessioned2019-08-12T05:00:08Z-
dc.date.available2019-08-12T05:00:08Z-
dc.date.issued2019-09-
dc.identifier.citationMedical Journal of Australia 2019; 211(5): 224-229en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/21396-
dc.description.abstractRepresentatives appointed by relevant Australian medical societies used a systematic approach for adaptation of guidelines (ADAPTE) to formulate clinical consensus recommendations on assessment and management of bone health in women with oestrogen receptor-positive early breast cancer receiving endocrine therapy. The current evidence suggests that women receiving adjuvant aromatase inhibitors and pre-menopausal woman treated with tamoxifen have accelerated bone loss and that women receiving adjuvant aromatase inhibitors have increased fracture risk. Both bisphosphonates and denosumab prevent bone loss; additionally, denosumab has proven anti-fracture benefit in post-menopausal women receiving aromatase inhibitors for hormone receptor-positive breast cancer. Women considering endocrine therapy need fracture risk assessment, including clinical risk factors, biochemistry and bone mineral density measurement, with monitoring based on risk factors. Weight-bearing exercise and vitamin D and calcium sufficiency are recommended routinely. Anti-resorptive treatment is indicated in women with prevalent or incident clinical or morphometric fragility fractures, and should be considered in women with a T score (or Z score in women aged < 50 years) of < - 2.0 at any site, or if annual bone loss is ≥ 5%, considering baseline bone mineral density and other fracture risk factors. Duration of anti-resorptive treatment can be individualised based on absolute fracture risk. Relative to their skeletal benefits, risks of adverse events with anti-resorptive treatments are low. Skeletal health should be considered in the decision-making process regarding choice and duration of endocrine therapy. Before and during endocrine therapy, skeletal health should be assessed regularly, optimised by non-pharmacological intervention and, where indicated, anti-resorptive treatment, in an individualised, multidisciplinary approach.en_US
dc.language.isoeng-
dc.subjectBreast neoplasmsen_US
dc.subjectOsteoporosisen_US
dc.titleAssessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement summary.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleMedical Journal of Australiaen_US
dc.identifier.affiliationUniversity of Melbourne, Melbourne, VICen_US
dc.identifier.affiliationAustin Healthen_US
dc.identifier.affiliationBarwon Health, Geelongen_US
dc.identifier.affiliationDeakin University, Geelong, VICen_US
dc.identifier.affiliationMonash Medical Centre, Melbourne, VICen_US
dc.identifier.affiliationMonash University, Melbourne, VICen_US
dc.identifier.affiliationMonash Centre for Health Research and Implementation, Monash University, Melbourne, VICen_US
dc.identifier.affiliationGarvan Institute of Medical Research, Sydney, NSWen_US
dc.identifier.affiliationConsumer Representative, Breast Cancer Network Australia, Melbourne, VICen_US
dc.identifier.affiliationMonash Partners Academic Health Sciences Centre, Monash University, Melbourne, VICen_US
dc.identifier.doi10.5694/mja2.50280en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0001-8261-3457en_US
dc.identifier.orcid0000-0001-7609-577Xen_US
dc.identifier.orcid0000-0001-8261-3457en_US
dc.identifier.pubmedid31318068-
dc.type.austinJournal Article-
local.name.researcherGrossmann, Mathis
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptEndocrinology-
crisitem.author.deptEndocrinology-
crisitem.author.deptMedicine (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

88
checked on Dec 22, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.